IDEAS home Printed from https://ideas.repec.org/a/sae/medema/v39y2019i4p371-379.html
   My bibliography  Save this article

Toward a Centralized, Systematic Approach to the Identification, Appraisal, and Use of Health State Utility Values for Reimbursement Decision Making: Introducing the Health Utility Book (HUB)

Author

Listed:
  • Feng Xie

    (Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada
    Program for Health Economics and Outcome Measures (PHENOM), Hamilton, ON, Canada
    Centre for Health Economics and Policy Analysis, McMaster University, Hamilton, ON, Canada)

  • Michael Zoratti

    (Department of Health Research Methods, Evidence and Impact (formerly Clinical Epidemiology and Biostatistics), McMaster University, Hamilton, ON, Canada)

  • Kelvin Chan

    (Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada
    Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada)

  • Don Husereau

    (Institute of Health Economics, Edmonton, Alberta, Canada
    Faculty of Health Sciences, University of Ottawa, Ottawa, ON, Canada)

  • Murray Krahn

    (Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada)

  • Oren Levine

    (Department of Oncology, McMaster University, Hamilton, ON, Canada)

  • Tammy Clifford

    (School of Epidemiology and Public Health, University of Ottawa, Ottawa, ON, Canada)

  • Holger Schunemann

    (Department of Health Research Methods, Evidence and Impact (formerly Clinical Epidemiology and Biostatistics), McMaster University, Hamilton, ON, Canada)

  • Gordon Guyatt

    (Department of Health Research Methods, Evidence and Impact (formerly Clinical Epidemiology and Biostatistics), McMaster University, Hamilton, ON, Canada)

Abstract

Cost-utility analysis (CUA) is a widely recommended form of health economic evaluation worldwide. The outcome measure in CUA is quality-adjusted life-years (QALYs), which are calculated using health state utility values (HSUVs) and corresponding life-years. Therefore, HSUVs play a significant role in determining cost-effectiveness. Formal adoption and endorsement of CUAs by reimbursement authorities motivates methodological advancement in HSUV measurement and application. A large body of evidence exploring various methods in measuring HSUVs has accumulated, imposing challenges for investigators in identifying and applying HSUVs to CUAs. First, large variations in HSUVs between studies are often reported, and these may lead to different cost-effectiveness conclusions. Second, issues concerning the quality of studies that generate HSUVs are increasingly highlighted in the literature. This issue is compounded by the limited published guidance and methodological standards for assessing the quality of these studies. Third, reimbursement decision making is a context-specific process. Therefore, while an HSUV study may be of high quality, it is not necessarily appropriate for use in all reimbursement jurisdictions. To address these issues, by promoting a systematic approach to study identification, critical appraisal, and appropriate use, we are developing the Health Utility Book (HUB). The HUB consists of an HSUV registry, a quality assessment tool for health utility studies, and a checklist for interpreting their use in CUAs. We anticipate that the HUB will make a timely and important contribution to the rigorous conduct and proper use of health utility studies for reimbursement decision making. In this way, health care resource allocation informed by HSUVs may reflect the preferences of the public, improve health outcomes of patients, and maintain the efficiency of health care systems.

Suggested Citation

  • Feng Xie & Michael Zoratti & Kelvin Chan & Don Husereau & Murray Krahn & Oren Levine & Tammy Clifford & Holger Schunemann & Gordon Guyatt, 2019. "Toward a Centralized, Systematic Approach to the Identification, Appraisal, and Use of Health State Utility Values for Reimbursement Decision Making: Introducing the Health Utility Book (HUB)," Medical Decision Making, , vol. 39(4), pages 371-379, May.
    • Handle: RePEc:sae:medema:v:39:y:2019:i:4:p:371-379
    DOI: 10.1177/0272989X19837969
    as

    Download full text from publisher

    File URL: https://journals.sagepub.com/doi/10.1177/0272989X19837969
    Download Restriction: no
    File URL: https://libkey.io/10.1177/0272989X19837969?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Roberta Ara & John Brazier & Tessa Peasgood & Suzy Paisley, 2017. "The Identification, Review and Synthesis of Health State Utility Values from the Literature," PharmacoEconomics, Springer, vol. 35(1), pages 43-55, December.
    2. Peasgood, T & Ward, S & Brazier, J, 2010. "A review and meta-analysis of health state utility values in breast cancer," MPRA Paper 29950, University Library of Munich, Germany.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Dirk Müller & Marion Danner & Rita Schmutzler & Christoph Engel & Kirsten Wassermann & Björn Stollenwerk & Stephanie Stock & Kerstin Rhiem, 2019. "Economic modeling of risk-adapted screen-and-treat strategies in women at high risk for breast or ovarian cancer," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(5), pages 739-750, July.
    2. Lin Li & J L (Hans) Severens & Olena Mandrik, 2019. "Disutility associated with cancer screening programs: A systematic review," PLOS ONE, Public Library of Science, vol. 14(7), pages 1-17, July.
    3. Patricia Blank & Martin Filipits & Peter Dubsky & Florian Gutzwiller & Michael Lux & Jan Brase & Karsten Weber & Margaretha Rudas & Richard Greil & Sibylle Loibl & Thomas Szucs & Ralf Kronenwett & Mat, 2015. "Cost-Effectiveness Analysis of Prognostic Gene Expression Signature-Based Stratification of Early Breast Cancer Patients," PharmacoEconomics, Springer, vol. 33(2), pages 179-190, February.
    4. Nasuh C. Büyükkaramikli & Saskia Groot & Rob Riemsma & Debra Fayter & Nigel Armstrong & Piet Portegijs & Steven Duffy & Jos Kleijnen & Maiwenn J. Al, 2019. "Ribociclib with an Aromatase Inhibitor for Previously Untreated, HR-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technol," PharmacoEconomics, Springer, vol. 37(2), pages 141-153, February.
    5. Roberta Ara & John Brazier & Ismail Azzabi Zouraq, 2017. "The Use of Health State Utility Values in Decision Models," PharmacoEconomics, Springer, vol. 35(1), pages 77-88, December.
    6. Michael J. Zoratti & A. Simon Pickard & Peep F. M. Stalmeier & Daniel Ollendorf & Andrew Lloyd & Kelvin K W Chan & Don Husereau & John E. Brazier & Murray Krahn & Mitchell Levine & Lehana Thabane & Fe, 2021. "Evaluating the conduct and application of health utility studies: a review of critical appraisal tools and reporting checklists," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 22(5), pages 723-733, July.
    7. Bromley, Hannah L. & Petrie, Dennis & Mann, G.Bruce & Nickson, Carolyn & Rea, Daniel & Roberts, Tracy E., 2019. "Valuing the health states associated with breast cancer screening programmes: A systematic review of economic measures," Social Science & Medicine, Elsevier, vol. 228(C), pages 142-154.
    8. Caroline S Clarke & Rachael M Hunter & Ian Shemilt & Victoria Serra-Sastre, 2017. "Multi-arm Cost-Effectiveness Analysis (CEA) comparing different durations of adjuvant trastuzumab in early breast cancer, from the English NHS payer perspective," PLOS ONE, Public Library of Science, vol. 12(3), pages 1-19, March.
    9. Gregory Katz & Olivier Romano & Cyril Foa & Anne-Lise Vataire & Jean-Victor Chantelard & Robert Hervé & Hugues Barletta & Axel Durieux & Jean-Pierre Martin & Rémy Salmon, 2015. "Economic Impact of Gene Expression Profiling in Patients with Early-Stage Breast Cancer in France," PLOS ONE, Public Library of Science, vol. 10(6), pages 1-15, June.
    10. Quang A. Le, 2016. "Structural Uncertainty of Markov Models for Advanced Breast Cancer," Medical Decision Making, , vol. 36(5), pages 629-640, July.
    11. Khadka, Jyoti & Kwon, Joseph & Petrou, Stavros & Lancsar, Emily & Ratcliffe, Julie, 2019. "Mind the (inter-rater) gap. An investigation of self-reported versus proxy-reported assessments in the derivation of childhood utility values for economic evaluation: A systematic review," Social Science & Medicine, Elsevier, vol. 240(C).
    12. Roberta Ara & Donna Rowen & Clara Mukuria, 2017. "The Use of Mapping to Estimate Health State Utility Values," PharmacoEconomics, Springer, vol. 35(1), pages 57-66, December.
    13. Nathaniel Hendrix & David D. Kim & Krishna S. Patel & Beth Devine, 2021. "Differences in the Selection of Health State Utility Values by Sponsorship in Published Cost-Effectiveness Analyses," Medical Decision Making, , vol. 41(3), pages 366-372, April.
    14. Micah Rose & Stephen Rice & Dawn Craig, 2018. "Does Methodological Guidance Produce Consistency? A Review of Methodological Consistency in Breast Cancer Utility Value Measurement in NICE Single Technology Appraisals," PharmacoEconomics - Open, Springer, vol. 2(2), pages 97-107, June.
    15. Dirk Müller & Marion Danner & Kerstin Rhiem & Björn Stollenwerk & Christoph Engel & Linda Rasche & Lisa Borsi & Rita Schmutzler & Stephanie Stock, 2018. "Cost-effectiveness of different strategies to prevent breast and ovarian cancer in German women with a BRCA 1 or 2 mutation," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(3), pages 341-353, April.
    16. Claudine Bommer & Judith Lupatsch & Nicole Bürki & Matthias Schwenkglenks, 2022. "Cost–utility analysis of risk-reducing strategies to prevent breast and ovarian cancer in BRCA-mutation carriers in Switzerland," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 23(5), pages 807-821, July.
    17. Jiryoun Gong & Juhee Han & Donghwan Lee & Seungjin Bae, 2020. "A Meta-Regression Analysis of Utility Weights for Breast Cancer: The Power of Patients’ Experience," IJERPH, MDPI, vol. 17(24), pages 1-16, December.
    18. Kevin Kennedy & Gurkaran Sarohia & Dominik Podbielski & Simon Pickard & Jean-Eric Tarride & Feng Xie, 2024. "Systematic methodological review of health state values in glaucoma cost-utility analyses," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 25(8), pages 1417-1435, November.
    19. Sandjar Djalalov & Linda Rabeneck & George Tomlinson & Karen E. Bremner & Robert Hilsden & Jeffrey S. Hoch, 2014. "A Review and Meta-analysis of Colorectal Cancer Utilities," Medical Decision Making, , vol. 34(6), pages 809-818, August.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:sae:medema:v:39:y:2019:i:4:p:371-379. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: SAGE Publications (email available below). General contact details of provider: .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.